HAND2 and ovarian cancer: Growing evidence revealed that HAND2-AS1 suppressed tumor progression via multiple signaling pathways in various cancers, including endometrioid endometrial carcinoma [21, 22], head and neck squamous cell carcinoma [23], osteosarcoma [24, 25], colorectal cancer [26, 27], non-small cell lung cancer [28], esophagus squamous cell carcinoma [29], ovarian cancer [30], melanoma [31], and cervical squamous cell carcinoma [32].